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Abstract
Background:  Ischaemic stroke is a common disorder with genetic and environmental
components contributing to overall risk. Atherothromboembolic abnormalities, which play a
crucial role in the pathogenesis of ischaemic stroke, are often the end result of dysregulation of
lipid metabolism. The ATP Binding Cassette Transporter (ABCA1) is a key gene involved in lipid
metabolism. It encodes the cholesterol regulatory efflux protein which mediates the transfer of
cellular phospholipids and cholesterol to acceptor apolipoproteins such as apolipoprotein A-I
(ApoA-I). Common polymorphisms in this gene affect High Density Lipoprotein Cholesterol (HDL-
C) and Apolipoprotein A-I levels and so influence the risk of atherosclerosis. This study has
assessed the distribution of ABCA1 polymorphisms and haplotype arrangements in patients with
ischaemic stroke and compared them to an appropriate control group. It also examined the
relationship of these polymorphisms with serum lipid profiles in cases and controls.
Methods: We studied four common polymorphisms in ABCA1 gene: G/A-L158L, G/A-R219K, G/
A-G316G and G/A-R1587K in 400 Caucasian ischaemic stroke patients and 487 controls. Dynamic
Allele Specific Hybridisation (DASH) was used as the genotyping assay.
Results: Genotype and allele frequencies of all polymorphisms were similar in cases and controls,
except for a modest difference in the ABCA1 R219K allele frequency (P-value = 0.05). Using the
PHASE2 program, haplotype frequencies for the four loci (158, 219, 316, and 1587) were estimated
in cases and controls. There was no significant difference in overall haplotypes arrangement in
patients group compared to controls (p = 0.27). 2211 and 1211 haplotypes (1 = common allele, 2
= rare allele) were more frequent in cases (p = 0.05). Adjusted ORs indicated 40% and 46% excess
risk of stroke for these haplotypes respectively. However, none of the adjusted ORs were
statistically significant. Individuals who had R219K "22" genotype had a higher LDL level (p = 0.001).
Conclusion: Our study does not support a major role for the ABCA1 gene as a risk factor for
ischaemic stroke. Some haplotypes may confer a minor amount of increased risk or protection.
Polymorphisms in this gene may influence serum lipid profile.
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Background
Ischaemic stroke is a complex disorder. Hypertension and
dyslipidemia are known to influence atherosclerosis and
so predispose to ischaemic stroke. Hypercholesterolemia
increases the risk of stroke [1], while lipid lowering ther-
apy significantly reduces risk of stroke [2]. Low HDL has
also been reported as a risk factor for ischaemic stroke
[3,4]. Several genes involved in lipid metabolism such as
Paraoxonase (PON), Lipoprotein Lipase (LPL) and Fatty
Acid-Binding Protein 2 (FABP2) have been examined in
the stroke populations [5-8]. ApoE protein is involved in
cholesterol transport and some studies suggest ApoE *ε 4
and ApoE *ε 2 alleles are associated with higher risk and
lower risk of ischaemic stroke respectively, but this has not
been confirmed in all studies [9,10].
Homozygous mutations including deletions and poly-
morphisms of the ATP-binding cassette transporter 1
(ABCA1) cause Tangier disease, a rare autosomal recessive
disorder with congenital HDL deficiency and increased
risk of atherosclerosis. Heterozygous mutants develop
familial HDL deficiency in which less severe HDL defi-
ciency is associated with reduced cholesterol efflux, which
also predispose to atherosclerosis [11-13]. In the general
population, low plasma HDL cholesterol (HDL-C)
increases the risk of coronary artery disease (CAD) [14-
16]. Variations in ABCA1  gene and alteration in gene
expression have been shown to affect the risk of athero-
sclerosis in animal models [17,18] and invitro studies
show that ABCA1 also modulates LDL oxidation in the
artery wall cells [19]. ABCA1 gene expression is upregu-
lated in atherosclerotic plaques, further suggesting an
association between ABCA1 and atheroma [20]. Reports
have suggested a relationship between individual poly-
morphisms of ABCA1 gene and lipid profiles [21,22]. Fur-
thermore, ABCA1 appears to be required in neuronal
tissue for cholesterol efflux to ApoA-I and ApoE. ABCA1
deficiency in the brain causes a dramatic fall in neuronal
ApoE levels [23,24]. The only published study in ischae-
mic stroke on 244 Hungarian patients [25] suggests a pro-
tective role for the ABCA1-R219K and V771M
polymorphisms. The aim of this study was to assess the
distribution of different polymorphisms and haplotype
arrangements of the ABCA1  gene, and any association
with lipid profile, in a series of well-phenotyped ischae-
mic stroke patients and unaffected control subjects.
Methods
Subjects
After ethical committee approval and informed consent,
400 Caucasian patients admitted to a regional hospital
with a CT confirmed diagnosis of ischemic stroke were
recruited over a period of 3 years. Four hundred and
eighty seven Caucasian individuals from the same region,
without any clinical cerebrovascular disease were used as
controls. All were volunteers, 194 were part of a birth
cohort (Aberdeen Birth Cohort) born in 1921. The others
were recruited through general practices, so that overall
controls were roughly age matched to cases. For a sub-
group of controls (n = 181) detailed lipid parameters
including total cholesterol, VLDL-Cholesterol, VLDL-Trig-
lyceride, IDL, LDL, HDL2, HDL3 were available for com-
parison with ABCA1 genotypes.
Classification of stroke patients
On the basis of clinical, laboratory and radiological
parameters, all cases were assessed by an experienced
stroke physician according to Trial of Org 10172 in Acute
Stroke Treatment (TOAST) criteria [26] to determine
stroke subtype (Table 2). Haemorrhagic stroke cases were
not included. For most patients lipid levels were checked
either at admission or the following morning. No patients
included in this analysis were known to be on statin on
admission.
Genotyping method and markers
DNA was extracted using Nucleon® DNA extraction kits.
5–10ng DNA was amplified through Hot Start PCR proto-
col using Immolase Taq DNA polymerase®. We used dif-
ferent sets of primers for each SNP as follows:
1-  ABCA1-rs2230805  (G/A; L158L); designated as
[ABCA1-6]
ABCA1-2230805F: 5'-biotin-TAGACTTTGGGAGAGA-
GAGGTTGT-3'
ABCA1-2230805R: 5'-AATGAAACCTTCTCTGGGTTCC-3'
2-  ABCA1-rs2234884  (G1051A; R219K); designated as
[ABCA1-3]
ABCA1-2234884F: 5'-biotin-AATTTCTGAGCTTTGT-
GGACTA-3'
ABCA1-2234884R: 5'-GCTCTGCTGCAGTCATTTTCTC-3'
3-  ABCA1-rs2246841  (G888A; G316G); designated as
[ABCA1-5]
ABCA1-2246841F: 5'-biotin-TACCAGTTGAGAGACTT-
GATCTTC-3'
ABCA1-2246841R: 5'-TCTCGTATTGTCTGTGGGCATC-3'
4- ABCA1-rs1997618 (c/t, T1555I)
ABCA1-1997618F: 5'-biotin-CCGAGTCAAGAAGTTAAT-
GATGC-3'BMC Medical Genetics 2007, 8:30 http://www.biomedcentral.com/1471-2350/8/30
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ABCA1-1997618R: 5'-GCTTTAGGTGTTTCTTCATTT-
GTTT-3'
5- ABCA1-rs2234886 (G5155A; R1587K); designated as
[ABCA1-4]
ABCA1-2234886F: 5'-biotin-CAGCGGTTTACCTTGACAT-
TATT-3'
ABCA1-2234886R: 5'-GAAGATTTATGACAGGACT-
GGACAC-3'
6- ABCA1-rs1883024 (c/t, P1648L)
ABCA1-1883024F: 5'-biotin-TATACA-
GACACAGCCACACTTA-3'
ABCA1-1883024R: 5'-ATCTCACCAAGCAGCAGTTCTC-3'
Of the six ABCA1 SNPs, only four SNPs (G/A-L158L, G/A-
R219K, G/A-G316G and G/A-R1587K) were polymorphic
in the Scottish population. All had genotype frequencies
in Hardy Weinberg equilibrium. Genotyping assays for
determining different alleles were based on the Dynamic
Allele Specific Hybridisation (DASH) technique as
described by the developers [27]. Genotype scoring in this
method is based on the melting temperature curves of the
amplified DNA strand containing the polymorphic site
and its complementary specific probe in presence of a dye.
Data analysis
Association between markers and disease phenotype was
tested with Pearson χ2 test. To explore distribution of cat-
egorical data, hypertension and gender, between cases
and controls, chi-square test was used. Lipid parameters
were log transformed before analysis. Numerical covari-
ates, age, total cholesterol, HDL, LDL, total triglyceride
and glucose, were compared between cases and controls
by t-test. Smoking status was incomplete for a subgroup of
controls and therefore not included in analysis. A univar-
iate logistic regression method was carried out in order to
identify factors potentially associated with risk of stroke.
To control for the effect of confounding factors and cov-
ariates, multiple logistic regression with SPSS version 14
(Statistical Package for Social Science) was used for statis-
tical analysis. A p-value of less than or equal to 0.05 was
considered statistically significant.
ANOVA was used for comparing the effect of different
genotypes on lipid profiles. Independent samples T-test
was also used to compare means of different groups based
on quartiles or carrier status. Haplotype frequencies for
the four loci (G/A-L158L, G/A-R219K, G/A-G316G and
G/A-R1587K) were estimated for cases and controls, using
PHASE Ver.2.11 [28].
Results
Demographic parameters and serology results are shown
in Table 1.
Allelic distributions and genotype frequencies
ABCA1-6 (G/A; L158L) "G" allele frequency (L variant) in
cases and controls was 69.7% and 72.3% respectively (p =
0.25; OR = 0.88, 95%CI: 0.71–1.09). ABCA1-3 (G1051A;
R219K) "G" allele frequency (R variant) was 68.2% in
cases and 73.2% in controls (p = 0.05; OR = 0.79, 95%CI:
0.62–1.00), ABCA1-5 (G/A; G316G) "G" allele frequency
(G variant) was 88% in cases and 86.7% in controls (p =
0.42; OR = 1.13, 95%CI: 0.84–1.52); ABCA1-4 (G5155A;
R1587K) "G" allele frequency (R variant) was 77.4% in
cases and 75.9% in controls (p = 0.47; OR = 1.09, 95%CI:
0.86–1.37). After adjusting for confounding factors and
covariates, minor changes in the risk were not statistically
significant.
In addition to a trend to lower ABCA1-3 (G1051A;
R219K) "G" allele frequency in all cases (p = 0.05), espe-
cially in males (p = 0.04), the "22" genotype was higher in
LVD cases (p = 0.04) and also in patients over 65 years (p
Table 2: Different stroke subtypes based on TOAST 
classification
Subtype All Stroke Samples
Number %
Large Vessel Disease (LVD) 141 35.3%
Small Vessel Disease (SVD) 98 24.5%
Cardioembolic 76 19%
Other/Unclear 85 21.3%
Hemorrhagic Stroke 0 0
TOTAL 400 100%
Table 1: Specifications of cases and controls
Cases (n = 400) Controls (n = 487)
Mean age (± SD)§ 66 (± 11) 64.2(± 12.3)
Sex (M:F Ratio)§ 1.4 0.97
Hypertension*§ 41% 18%
Diabetes Mellitus**§ 12.2% 3.2%
Total Cholesterol mmol/l 
(Ave., SD)§
5.6 (± 1.3) 5.8 (± 1.2)
HDL mmol/l (Ave., SD)§ 1.2 (± 0.4) 1.4 (± 0.4)
LDL mmol/l (Ave., SD) 3.5 (± 1.2) 3.5 (± 1.1)
Total Triglyceride mmol/l 
(Ave., SD)
1.7 (± 1.1) 1.8 (± 1.1)
Glucose mmol/l§ 6.4 (± 2.4) 5.9 (± 1.2)
* Hypertension defined as blood pressure > 160/90 mmHg or history 
of hypertension/on hypertensive therapy
** History of diabetes or confirmed laboratory diagnosis
§Significant difference (P < 0.05) between cases and controlsBMC Medical Genetics 2007, 8:30 http://www.biomedcentral.com/1471-2350/8/30
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= 0.01), compared to controls. ABCA1-5 (G/A; G316G)
"11" genotype was also commoner in cases than in con-
trols (p = 0.04). However after adjusting OR for con-
founders the difference did not remain significant.
There were no significant differences in allele frequencies
between cases and controls in each gender group, or
between stroke TOAST subgroups for the other SNPs
tested.
Effects of genotypes on lipid profile
We also studied the effects of different ABCA1 genotypes
on lipid profile in all cases and controls. Cases with
ABCA1-3 (G1051A; R219K) "22" genotype had a higher
LDL level compared to controls which remained signifi-
cant after Bonferroni correction (p = 0.003). In 181 of the
controls who had a more detailed lipid profile, no differ-
ences were found in VLDL-Cholesterol, IDL, LDL, HDL2,
HDL3, total cholesterol and triglyceride levels in females
or males between different genotypes of ABCA1. How-
ever, in this subgroup, females with ABCA1-3 (G1051A;
R219K) "11" and ABCA1-4 (G5155A; R1587K) "22" gen-
otypes had a higher level of IDL (p = 0.01 and p = 0.02)
respectively.
Effects of alleles on lipid profile
Comparing the lipid profiles in carriers of different
ABCA1  alleles revealed that individuals who were the
ABCA1-R219K carrier (K allele) had a lower TG level than
non carriers (p = 0.005). This trend was observed in cases
(p = 0.017) but not in controls (p = 0.8). The lipid profile
of the population in the presence of different ABCA1 gene
alleles has been summarised in tables 3.
Haplotypes
Haplotype analysis was performed using PHASE version
2.11. The PHASE program [28], resulted in reconstruction
of 16 different haplotypes in cases and controls. Overall
haplotype frequencies in cases and controls were not
reported significantly different by the program (p = 0.27),
although there were differences in specific haplotypes
between the groups. Adjusted ORs indicated 40%, 27%
and 46% excess risk of stroke for haplotypes 2211, 2212
and 1211 respectively. However, none of these risks were
statistically significant (Table 4). The haplotypes arrange-
ments did not influence the lipid profile of cases or con-
trols.
Discussion
The ABCA1 gene is known to have a crucial role in lipid
metabolism [29,30]. Mutations or polymorphisms in this
gene are known to cause dyslipidemia such as low HDL-C
and thus predispose to atherosclerosis [31,32]. Several
polymorphisms of the ABCA1  gene have been investi-
gated for their association with CAD [33-35]. Other works
have reported that CAD patients who are carriers of
R219K allele had less severe atherosclerosis [31] and over-
all lower risk of CAD [36]. Andrikovics et al recently
reported a higher frequency of R219K in controls than in
Hungarian stroke patients and suggested a protective role
for this polymorphism [25]. By contrast, our control
group had a higher "R219" allele frequency, while the
stroke population had a higher "219K" allele frequency.
The "219K" allele frequency is similar to that reported in
other studies of Irish and other Scottish populations [36].
Two SNPs, P1648L and T1555I, were not polymorphic in
our population.
While the R219K -G1051A- (A or "K" variant) has been
associated with decreased TG, increased HDL and subse-
quently a lower risk for atherosclerotic progression, in
contrast the R allele has been associated with vascular dis-
ease [31]. This has not been confirmed in our study,
although in our stroke population those with R219K "22"
genotype (AA) had a higher level of LDL and the "K allele"
carriers had a lower TG. Clee et al also reported lower TG
in the carriers of 219K variant and this finding was repli-
cated in our population (p = 0.006). The HDL level
showed no significant difference among different R219K
genotypes.
It is also of interest that a protective role for the 219K
allele has not been confirmed by all studies. Ethnic back-
ground or other environmental factors may weaken the
link with HDL-C levels. However, in three other European
populations in contrast to a Japanese one, R219 has been
constantly the wild type allele [37].
Haplotype analysis can provide additional power in asso-
ciation studies in complex diseases [38]. Results using dif-
ferent programs are usually consistent, but sometimes
there are minor variations [6,39]. We performed haplo-
type analysis in the remaining four SNPs, and only the
2211 and 1211 haplotypes were more frequent in cases (p
= 0.05). Only a small proportion of individuals carried
these haplotypes, thus the result should be interpreted
with caution.
We found an association between LDL levels and ABCA1
genotype, but not with HDL. Epidemiological studies of
ABCA1 polymorphisms and HDL levels suggest that only
10% of HDL level variation maybe explained by this gene
[40] and thus our study may not have been large enough
to detect this. Other studies have shown an association
between the R219K polymorphism and MI, but no associ-
ation between haplotype arrangements and MI. Polymor-
phisms in the promoter region (C-564T) and in the
coding region (R1587K) have shown an association with
ApoA-I levels but these have not been associated with vas-
cular disease. Another study has suggested that rare allelesBMC Medical Genetics 2007, 8:30 http://www.biomedcentral.com/1471-2350/8/30
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Table 3: lipid profiles changes in different ABCA1 genotypes and allele carriers:
A. Lipid profile in carriers of different ABCA1 gene alleles in the whole population (cases and controls altogether)
Carrier 1
(11+12)
Non car.
(22)
p-value Carrier 2
(22+12)
Non car.
(11)
p-value
ABCA1-6 HDL 1.3597 1.3605 NS 1.3655 1.3545 NS
LDL 3.4775 3.5805 NS 3.4439 3.5273 NS
TC 5.6951 5.8002 NS 5.6163 5.7877 NS
TG 1.7831 1.7436 NS 1.6834 1.8690 0.017
ABCA1-3 HDL 1.3446 1.2960 NS 1.3566 1.3254 NS
LDL 3.5526 3.7406 NS 3.5246 3.6108 NS
TC 5.7511 5.7903 NS 5.6764 5.8295 NS
TG 1.7837 1.6215 NS 1.6546 1.8804 0.005
ABCA1-5 HDL 1.3587 1.4355 NS 1.4073 1.3456 NS
LDL 3.4945 3.4193 NS 3.4848 3.4956 NS
TC 5.7044 5.6052 NS 5.6795 5.7095 NS
TG 1.7832 1.5616 NS 1.6355 1.8233 0.014
ABCA1-4 HDL 1.3658 1.2838 NS 1.3338 1.3818 NS
LDL 3.4783 3.6276 NS 3.5464 3.4413 NS
TC 5.6993 5.7631 NS 5.7841 5.6434 NS
TG 1.7690 1.7868 NS 1.7727 1.7679 NS
B. Lipid profile in carriers of different ABCA1 gene alleles in controls
ABCA1-6 HDL 1.4429 1.4804 NS 1.4578 1.4350 NS
LDL 3.4442 3.4792 NS 3.4147 3.4762 NS
TC 5.8044 5.9003 NS 5.7374 5.8794 NS
TG 1.8046 1.7877 NS 1.7099 1.8881 NS
ABCA1-3 HDL 1.4416 1.4097 NS 1.4681 1.4143 NS
LDL 3.4805 3.5634 NS 3.4173 3.5464 NS
TC 5.8415 5.8622 NS 5.7426 5.9319 NS
TG 1.8264 1.7660 NS 1.7310 1.9042 NS
ABCA1-5 HDL 1.4473 1.3916 NS 1.4920 1.4311 NS
LDL 3.4534 3.5611 NS 3.4592 3.4540 NS
TC 5.8155 5.6472 NS 5.7071 5.8175 NS
TG 1.8143 1.4965 NS 1.7026 1.8433 NS
ABCA1-4 HDL 1.4528 1.3398 NS 1.4143 1.4712 NS
LDL 3.4343 3.5858 NS 3.5336 3.3742 NS
TC 5.7987 5.8264 NS 5.8773 5.7429 NS
TG 1.7965 1.8134 NS 1.7893 1.8036 NS
C. Lipid profile in different carriers of ABCA1 gene alleles in cases
ABCA1-6 HDL 1.2357 1.2333 NS 1.2362 1.2348 NS
LDL 3.5242 3.6879 NS 3.4813 3.6015 NS
TC 5.4888 5.7000 NS 5.4662 5.6623 NS
TG 1.7499 1.6923 NS 1.6447 1.8395 NS
ABCA1-3 HDL 1.2123 1.2107 NS 1.2217 1.2024 NS
LDL 3.6464 3.8690 NS 3.6485 3.7008 NS
TC 5.6403 5.7424 NS 5.6057 5.7004 NS
TG 1.7236 1.5037 NS 1.5596 1.8459 0.017
ABCA1-5 HDL 1.2319 1.4857 NS 1.2691 1.2288 NS
LDL 3.5502 3.2571 NS 3.5243 3.5494 NS
TC 5.5619 5.5571 NS 5.5079 5.5766 NS
TG 1.7372 1.6483 NS 1.5243 1.7948 0.016
ABCA1-4 HDL 1.2452 1.1867 NS 1.2169 1.2603 NS
LDL 3.5358 3.7000 NS 3.5640 3.5282 NS
TC 5.5760 5.6533 NS 5.6622 5.5212 NS
TG 1.7292 1.7407 NS 1.7480 1.7166 NSBMC Medical Genetics 2007, 8:30 http://www.biomedcentral.com/1471-2350/8/30
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with major phenotypic effects contribute significantly to
low plasma HDL [41]. Although lipid measurements were
made early after admission, possible confounders include
the acute lipid changes that occur after acute stroke. The
lipid levels reported in our study are similar to those val-
ues on the morning after admission reported by Dyker,
Weir and Lees in patients after acute stroke [42]. The
changes in lipids post stroke remain controversial, but fur-
ther studies of changes in lipid profile will be difficult
because of the early introduction of statin therapy on the
basis of studies such as SPARCL [43].
Conclusion
In conclusion ABCA1 was not associated with ischaemic
stroke in our population. Among the studied ABCA1 gene
polymorphisms, R219K has the greatest impact on lipid
profile especially LDL and TG. Large scale epidemiological
studies may be necessary to definitively confirm an asso-
ciation of this gene with specific vascular diseases.
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